close
MENU
Chief reporter
Chief reporter

Will Mace

Will Mace began his journey in business journalism at The Independent circa 2009, but when that weekly business paper was closed down he became a founding reporter for the Fairfax Business Bureau, which supplied news to Fairfax’s regional mastheads and the Stuff.co.nz website.

Moving to London in 2013, he spent six years at Acuris Global (formerly Mergermarket) covering listed M&A deals, event-driven special situations, and shareholder activism campaigns across Europe for an investment banking and hedge fund audience. In 2016 he was tasked with launching an entirely new Acuris service called Activistmonitor, and became an authority on the subject of investor activism as it grew in the region.

Over his last two years in London, Will juggled editorship and reporting across activism, M&A, ECM, and regulatory/competition review coverage. He joined NBR in April 2021.

He enjoys live music, sailing, skiing, and critiquing rugby from the safety of the sidelines. 

Will Mace's Articles

How digital identity could free us from big tech dependency

Read Article
Mon, 01 Sep 2025

Air NZ suffers up to $320m impact from engine maintenance saga

Read Article
Thu, 28 Aug 2025

Featured Rich Lister: Hamish Edwards

Read Article
Thu, 28 Aug 2025

FMA investigating trading in Rakon’s shares

Read Article
Wed, 27 Aug 2025

AI demand will prove fibre’s superiority over 5G, says Chorus

Read Article
Mon, 25 Aug 2025

Eroad’s co-CEOs happy to share the driver’s seat

Read Article
Mon, 25 Aug 2025

‘Shut up’: Accusations fly as Rakon chair withdraws from election

Read Article
Fri, 22 Aug 2025

Rakon chair reverses board retirement over AGM ructions

Read Article
Thu, 21 Aug 2025

Auckland Airport upgrade on schedule but outlook remains cloudy

Read Article
Thu, 21 Aug 2025

Market reacts positively to Spark’s dividend reset, new strategy

Read Article
Wed, 20 Aug 2025

Queenstown Airport profit up 78%, declares $19m dividend

Read Article
Wed, 20 Aug 2025

Momentum & PCRN to merge as clinical research roll-up continues

Read Article
Tue, 19 Aug 2025
1 3 4 5 6 7 106